Title | Origin | Methodology | Participants | Indication | Dose | Outcome |
Intravenous MP pulse as treatment for hospitalized covid-19 critical patients: results of a randomized controlled trial4 | Iran | Randomized Clinical Trial | 68 TOTAL 34: MP intervention, 28: Standard, 06: deleted | Early pulmonary phase (Non-IOT Patients) | Methylprednisolone 250 mg (03 days) | Mortality rate was lower in the Methylprednisolone group (5.9% versus 42.9%; p < 0.001). |
Efficacy of MP pulse therapy in patients with COVID-192 | Russia | Retrospective Analysis | 57 | ??? | Methylprednisolone 500 mg (03 days) | Decrease in inflammatory tests. No patients transferred to the ICU. |
Impact of Corticosteroids on Coronavirus Disease Results 201918 | USA | Systematic Review | Review of 73 studies (21,350 patients). Database (PubMed, MEDLINE and EMBASE) of the literature published until July 22, 2020, | Critically ill patients under mechanical ventilation or in an ICU environment. | Varied | Corticosteroids showed benefit in critically ill patients.(OR, 0.65; 95% CI, 0.51 - 0.83; p = 0.0006). However, it was not possible to identify a greater benefit according to high or low dose regimens. The analysis was limited by highly heterogeneous literature for high-dose and low-dose corticosteroid regimens. |
MP pulses in the second week improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data.19 | Spain | Comparative observational study | 242 patients with COVID-19 and elevation of inflammatory markers | From the 8th day | 125 - 250 mg/d x3 | The HR adjusted for death and death or IOT for patients in the MP group was 0.35 (95% CI 0.11 to 1.06, p = 0.064) and 0.33 (95% CI 0.13 to 0.84, p = 0.020), respectively. This difference was specifically seen in the subcohort of patients with spo2/fio2 ratio lower than 353 on the 7 day of disease. |
High dose, short-term corticosteroids for ARDS caused by COVID-19: a number of cases.12 | Japan | Case series | 07 | Critically ill patients under IOT | 500 - 1000 mg/day (03 days) MP followed by 1 mg/kg in progressive reduction. | All patients extubated within 07 days. |
The Effects of Steroids in Severe Hospitalized Patients with COVID-19: A Retrospective Cohort Study20. | China | retrospective, two-centred, cohort study | 760 hospitalized. 659 patients were excluded because In total, 101 included: 39 in the steroid group and 63 in the non-steroid group | ? | median dose of MP was 80 mg daily (40 - 160 mg daily), and 38 (90.5%) received methylprednisolone or equivalent < 150 mg. CTCD was initiated within 13 days (9 - 22 days) | short-term corticosteroids at low to moderate doses did not improve the clinical outcomes for patients with severe COVID-19. |